Study of FCN-098 in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2024-10-12
Target enrollment:
Participant gender:
Summary
A multi-center, open, single-arm phase I dose exploratory study to evaluate the safety,
tolerability, pharmacokinetic characteristics and primary antitumor activity of FCN-098 in
patients with advanced solid tumors.